Login
$ACOG
$7.83 -$0.47 (5.66%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Michael McFadden Also a director
CEO
58 Since 2021
5 years
Not stated $3,624,181
Henry Du
Vice President of Finance and Accounting and interim Chief Financial Officer
48 Since 2024
2 years
Not stated $464,506
Lauren D’Angelo
Chief Commercial Officer and Chief Operating Officer
47 Not stated 2021 $2,408,591

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 30, 2026 · updated by the 8-Ks of Jun 23, 2026 and Nov 12, 2026

Directors
7
serving now
Independent
4 of 4
stated in the proxy; 3 not stated
Average tenure
4.2 years
from year joined
CEO also chairs the board
No
Robert Wills
Director Age On board Independent Other public boards 2025 pay Source
Robert Wills
72 2025
1 year
Independent Milestone Pharmaceuticals, Inc., Oncternal Therapeutics $185,000
Michael McFadden
58 2021
5 years
Not stated None stated Paid as CEO
Kenneth Cawkell
74 2021
5 years
Not stated Westmount Minerals Corp., Portofino Resources Inc., Centurion Minerals Inc., Well Health Technologies Corp. $246,000
Rajeev “Rob” Bakshi
66 2017
9 years
Independent None stated $248,500
Phillip Mertz
41 2021
5 years
Independent None stated Not stated
Bethany Sensenig
50 2026
this year
Independent Supernus Pharmaceuticals, KalVista Pharmaceuticals Not stated
Caren Deardorf Joined Nov 11, 2026
- - - - -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

1 disclosed in the proxy filed Apr 30, 2026
Neurodyn Life Sciences Inc.
a former related party through common shareholders and management
US$1,400,000
March 2015

Promissory note issued by the Company to Neurodyn, later amended to change interest rate and maturity date.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support